Crinetics Presents Clinical and Research Results at ENDO 2022 SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational...

Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting - Late-breaking Poster Presentation on Sunday, October 3, 2021 SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company...

New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting Preclinical Data from XOMA’s Novel Anti-IL-2 Immuno-oncology Monoclonal Antibodies Program to be Presented at SITCAdvancing Unique Functional Antibody Antagonists Targeting the Parathyroid Hormone...

Rockwell Medical Enters Into Exclusive License Agreement With Wanbang Biopharmaceutical Co., Ltd. to Commercialize Triferic® in China WIXOM, Mich., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...